期刊
CANCER TREATMENT REVIEWS
卷 41, 期 10, 页码 893-903出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2015.09.004
关键词
Programmed death; PD-1; PD-L1; Gastrointestinal cancer; Immunotherapy; Immune checkpoint blockade
类别
资金
- National Health Service
- National Institute for Health Research Academic Clinical Fellowship
- Cancer Research UK
Immunotherapy represents a major breakthrough in cancer therapy in recent years. Immune-checkpoint blockade using PD-1 and PD-L1 antibodies appears to be one of the most promising immunotherapy approaches. Immunotherapy differs from conventional cancer treatment because of its ability to produce durable responses in some patients. In this review article, we explore the available evidence and summarise current clinical trials for PD-1 and PD-L1 blockade in gastrointestinal malignancies. The challenge now is to develop strategies to increase the efficacy of PD-1 and PD-L1 blockade in gastrointestinal cancer patients, such as combination therapy with chemotherapy, radiotherapy or other immunotherapy, along with validating biomarkers to select patients and personalise treatment. (C) 2015 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据